Bioseeker, Feb 2011
and the accumulated number of ceased drugs over the last years amount to another 136 (128) drugs. Angiogenesis In OncologyDrugPipelineUpdate lists all drugs and gives you a progress analysis on each one of them
Global Industry Analysts, Inc., Feb 2011, Pages: 682
Breakdown Based on Relative
Oncology Application (includes corresponding Graph/Chart) 22
Cilengitide 23
Imiquimod 23
Angiogenesis Inhibitors - Pipeline Status 24
Select Anti-AngiogenesisDrugs in Phase
Bioseeker, Jan 2012
Route to Consider Your Options and Position of Others
Angiogenesis in Oncology: DrugPipelineUpdate 2011-
The Package Includes
- A progress analysis on current and emerging drugs
- Information on most
Bioseeker, May 2007
- Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology and Angiogenesis in Oncology: DrugPipelineUpdate 2007-.
The Package Includes:
A progress analysis on current and emerging drugs
La Merie, Sep 2009, Pages: 133
widely accepted and has emerged as a valid therapeutic target in oncology. Vascular endothelial growth factor (VEGF) represents a key mediator of tumor-initiated angiogenesis and the first target
Datamonitor, April 2010, Pages: 243
with greater efficacy
Small molecules
Small molecules targeting tyrosine kinases have been a significant development in oncologydrug discovery
Classification of pipeline products
Angiogenesis inhibitor
Bioseeker, Sep 2007, Pages: 500
by Cancer Indications
7.3 Deployment of Natural Product Compounds by Cancer Indications
8 Drug Development in Oncology by Major Targeted Therapy Areas
8.1 Angiogenesis
8.2 Antibodies
8.3 Apoptosis
8
Bioseeker, Dec 2007, Pages: 430
Oncology Antibody Drug Targets
Table 2: Cancer Antibody Pipeline Listed by Carboxypeptidase Activity Targets
Table 3: Cancer Antibody Pipeline Listed by Catalytic Activity Targets
Table 4: Cancer Antibody
GlobalData, Dec 2010, Pages: 203
in Prostate Cancer Pipeline
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs
5.5.2 Molecules with Novel Mechanism of Action Strengthening
La Merie, July 2009, Pages: 20
in research and development of Bcr-Abl and Src kinase inhibitors in oncology and other indications. In addition, the report lists company-specific R&D pipelines of Bcr-Abl and Src kinase inhibitors. Competitor projects
Global Markets Direct, Nov 2011, Pages: 126
” provides data on the Peregrine Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features
La Merie, Nov 2009, Pages: 37
of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report
Bioseeker, Jan 2007, Pages: 750
this analysis to drive strategic planning decisions in oncologydrug development TOP 7 CANCER INDICATIONS
THERAPEUTIC & COMPETITIVE INSIGHTS
1 EXECUTIVE SUMMARY
2 TABLE OF CONTENTS
21 LIST BOXES
22 LIST
Global Markets Direct, Nov 2011, Pages: 102
.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data
Espicom Business Intelligence Ltd, July 2007, Pages: 306
Scint.
Validation of PSMA Prognostic Value
ProstaScint Market Opportunity
Development Pipeline
Abtides
Oral Drug Delivery Technology
Clinical Trials
CYT-500 Radiolabelled Monoclonal Antibody
Quadramet Phase II Study
Informa Healthcare, March 2003, Pages: 456
the Pipeline: Results of Phase I and II Studies of New Drugs, C. Sternberg
Chemotherapy in the Management of Prostate Cancer, C. Logothetis and R.E. Millikan Prostate and Renal Cancer, Benign Prostatic
